Format

Send to

Choose Destination
Am J Pathol. 2016 Dec;186(12):3225-3235. doi: 10.1016/j.ajpath.2016.08.020. Epub 2016 Oct 15.

Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series.

Author information

1
Division of Immunology, Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland. Electronic address: pcat@jhmi.edu.
2
Division of Immunology, Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland; Department of Medicine, G. D'Annunzio University of Chieti, Chieti, Italy.
3
Endocrinology Unit, Saints Anthony and Biagio, and Cesare Arrigo Hospital, Alessandria, Italy; Oncology Center, Saints Anthony and Biagio, and Cesare Arrigo Hospital, Alessandria, Italy.
4
Oncology Center, Saints Anthony and Biagio, and Cesare Arrigo Hospital, Alessandria, Italy.
5
Division of Immunology, Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland.
6
Department of Radiology, Mesothelioma Unit, Saint Spirit Hospital, Casale Monferrato, Italy.
7
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
8
Department of Endocrinology, University of Pisa, Pisa, Italy.

Abstract

Hypophysitis that develops in cancer patients treated with monoclonal antibodies blocking cytotoxic T-lymphocyte-associated protein 4 (CTLA-4; an inhibitory molecule classically expressed on T cells) is now reported at an incidence of approximately 10%. Its pathogenesis is unknown, in part because no pathologic examination of the pituitary gland has been reported to date. We analyzed at autopsy the pituitary glands of six cancer patients treated with CTLA-4 blockade, one with clinical and pathologic evidence of hypophysitis, one with mild lymphocytic infiltration in the pituitary gland but no clinical signs of hypophysitis, and four with normal pituitary structure and function. CTLA-4 antigen was expressed by pituitary endocrine cells in all patients but at different levels. The highest levels were found in the patient who had clinical and pathologic evidence of severe hypophysitis. This high pituitary CTLA-4 expression was associated with T-cell infiltration and IgG-dependent complement fixation and phagocytosis, immune reactions that induced an extensive destruction of the adenohypophyseal architecture. Pituitary CTLA-4 expression was confirmed in a validation group of 37 surgical pituitary adenomas and 11 normal pituitary glands. The study suggests that administration of CTLA-4 blocking antibodies to patients who express high levels of CTLA-4 antigen in the pituitary can cause an aggressive (necrotizing) form of hypophysitis through type IV (T-cell dependent) and type II (IgG dependent) immune mechanisms.

PMID:
27750046
PMCID:
PMC5225294
DOI:
10.1016/j.ajpath.2016.08.020
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center